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Summary 
In this study, we have used a newly generated monoclonal antibody (mAb C1.7)  to identify 
a novel 38-kD signal-transducing surface molecule (p38) expressed by lymphocyte subsets capable 
of cell-mediated cytotoxicity.  Virtually  all  CD16+/CD56 +  natural  killer  (NK)  cells  and 
approximately half of CD8 §  (T cell receptor [TCR] ot//$ +) T  cells and TCR-3,//~ + T  cells 
express the p38 surface molecule. Stimulation of p38 on NK cells with mAb C1.7 activated 
cytotoxicity, induced lymphokine production, and initiated polyphosphoinositol turnover and 
[Ca2+]i  increases.  Unlike  other  NK  cell  surface  molecules that  activate  cytotoxicity,  p38 
stimulation did not result in the release of the granule enzyme N-carbobenzoxy-t-thiobenzyl 
ester-esterase  even under conditions in which mAb C1.7 induced NK cell-mediated redirected 
lysis of Fcq,  R + target cells. Activated (recombinant interleukin 2 [rlL-2],  5 d) CD8 + T  cells 
mediated  non-major  histocompatibility  complex  (MHC)-restricted  cytotoxicity,  and  the 
CD8 +/p38 + subset contained the overwhelming majority of this activity.  F(ab')2 fragments of 
mAb C1.7 inhibited non-MHC-restricted cytotoxicity mediated by resting NK cells and rlL-2- 
cultured T cells but did not affect spontaneous cytotoxicity mediated by activated, cultured NK 
cells. Taken as a whole, our results suggest that p38 may have a direct role in the recognition, 
signal transduction, and/or lytic mechanisms of non-MHC-restricted cytotoxicity. 
C 
Ytotoxic lymphocytes are a critical effector arm of cell- 
mediated immune responses to intracellular parasitic (bac- 
terial or viral) infections and tumors. These cytotoxic cells 
recognize target cells by at least two distinct mechanisms. 
The first mechanism, which is mediated by CTL, involves 
the interaction of the CTL with the target cell via recogni- 
tion of MHC class I or, less frequently, class II and antigenic 
peptides by clonally distributed TCR (1). This recognition 
is highly specific, elicits, memory, and has been termed MHC- 
restricted cytotoxicity. By contrast, the second mechanism 
is mediated primarily by CD3-, CD16 +, and CD56 + NK 
cells, which recognize target cells through possibly multiple 
and heterogeneous interactions of still incompletely charac- 
terized receptor/ligand pairs that are not directly restricted 
by MHC recognition. Cytotoxic effectors mediating this type 
of recognition and lysis are termed non-MHC-restricted cyto- 
toxic  cells  (2).  Although non-MHC-restricted  cytotoxic 
effectors are less specific than CTL and do not generate im- 
munologic memory responses, their early activation during 
an immune response and their broad lytic abilities make them 
an important effector component of natural resistance, active 
as a first line of defense well before specific effector mecha- 
nisms have been elicited. 
Resting NK cells express a number of surface molecules 
which, when stimulated, can activate their cytotoxic mecha- 
nism. The low affinity Fc receptor for IgG (Fc3,RIII or CD16) 
is expressed by virtually all human NK cells as well as a minor 
population of T cells, and when triggered by IgG antibodies 
on a  target  cell  surface induces antibody-dependent, cell- 
mediated cytotoxicity (3, 4). In addition, the CD2 molecule, 
which is expressed by 80-90%  of NK cells and recognizes 
CD58 or CD59 ligands on target cells, can also activate NK 
cells cytolytically (5-7).  Neither CD16 nor CD2 appear to 
be required for non-MHC-restricted cytotoxicity, as cyto- 
toxic lymphocytes that lack either molecule can still mediate 
natural killing (3, 8, 9). Other surface molecules with un- 
known ligands have recently been identified on NK cells that 
can also activate cytotoxicity. NKRP1 was identified on rat 
NK cells and an antibody against this molecule (mAb 3.2.3) 
can induce redirected lysis of Fcq,  R + target cells as well as 
other activation and signal transduction events (10). The cloned 
cDNA for NKRP1 encodes a putative type II integral mem- 
brane protein with significant homology (22%) with members 
of the C-type lectin superfamily (11). The NKI.1 antigen 
expressed by murine NK cells can initiate many of the activa- 
tion events observed with NKRP1  stimulation, and upon 
cloning of the cDNA coding for NKI.1 was found to be the 
murine equivalent of NKRP1 (12, 13). In humans, a family 
of related cDNAs (NKG2) was identified with restricted ex- 
pression to NK cells and codes for putative polypeptides dis- 
playing homology with NKRP1 (14). Additional molecules, 
such as pNKR1 (15), the molecules reacting with the mAbs 
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by mAb PP35 (19), although not structurally related  to the 
NKR.P1 family members, also appear to be activating struc- 
tures on NK cells. 
Although NK cell-mediated killing is not MHC restricted, 
it is not always MHC  independent.  On certain  target  cell 
types the level of MHC class I expression inversely correlates 
with the sensitivity of the target cell to NK cell lysis (20-24). 
One of the interpretations advanced to explain these findings 
is the missing self model, which hypothesizes that NK cells 
recognize  and lyse target  cells that  are low or deficient in 
MHC class I expression or possibly target cells that express 
allogeneic class I (25). This model has been used to explain 
the phenomenon of murine hybrid resistance and the specificity 
of human NK cell alloreactive clones (26-28).  Two alterna- 
tive mechanisms have been proposed to account for the effects 
of class I on NK cell activity.  MHC class I expression may 
mask the target cell antigen responsible for recognition by 
and activation of NK cells, or MHC class I recognition by 
the NK cell may deliver a negative  signal to lysis.  Recent 
studies  (29)  support  the negative  signal hypothesis  and in 
fact one NK cell surface  molecule has now been identified 
that appears  to be inhibitory to NK cell cytotoxicity  upon 
ligation. Ly-49 not only displays characteristics  of an inhibi- 
tory receptor but also appears to be directly involved in MHC 
class I recognition (30). In addition, the molecules identified 
by the antibodies SW5E6  (31-33)  or GL183/EB6  (34,  35) 
have also been proposed to recognize class I. Although it is 
now clear  that the expression of class I by target  cells can 
affect  NK cell-mediated  lysis,  it is likely that  non-MHC- 
restricted  cytotoxicity  can  occur  through  both  MHC- 
independent  and  -dependent  mechanisms  (36-39). 
Here we report the identification of a novel 38-kD signal 
transduction  surface molecule  (p38)  expressed  by virtually 
all human (CD3-/CD16 +/CD56 +) NK cells and subpopu- 
lations of T  cells comprising approximately half of CD8 + 
T cells and "y/~ + T cells.  Perturbation  of p38 with the anti- 
p38  antibody  mAb  C1.7  stimulated  NK  cell-mediated 
redirected cytotoxicity and under certain  experimental con- 
ditions induced lymphokine  (IFN-y  and IL-8) production 
and modulated proliferation. Upon crosslinking, mAb C1.7 
induced  polyphosphoinositide  turnover  and  increases  in 
[Ca2+]i  in purified,  cultured  NK  cells.  On  rlL-2-cultured 
(5  d)  CD8 +  T  cells  p38  was  shown  to  be  a  marker  for 
non-MHC-restricted cytotoxicity activity as suggested by the 
observation  that only p38 + and not p38-  T  cells had the 
ability to lyse a variety of NK cell-sensitive  and -resistant 
target cells.  In addition, the findings that F(ab')2 fragments 
of mAb  C1.7  inhibited  non-MHC-restricted  cytotoxicity 
mediated by resting NK cells or rlL-2-activated T cells sug- 
gest that p38 may have a role in target  cell recognition and 
cell-mediated  cytotoxicity. 
Materials  and Methods 
mAb C1.TPreparation.  6-wk-old female BALB/c mice were im- 
munized intraperitoneally with 20  x  10  ~ purified, cultured human 
NK cells, followed by four intraperitoneal injections of NK cells 
in a 5-mo period. The animals were then injected intravenously 
with the same amount of NK cells and after 3 d the mice were 
killed and a spleen cell suspension was prepared and then fused 
with the BALB/c  myeloma  cell line PX63.Ag8.653.  The fused cells 
were cloned by limiting dilution and the resultant hybridomas  were 
labeled with nCr and screened for their ability to activate NK cell 
cytotoxicity in a standard 3-h chromium release assay. The C1.7 
hybridoma producing the IgG1 C1.7 antibody was selected for fur- 
ther study on the basis of its ability to be efficiently lysed by the 
NK effector cells. 
Cell Lines.  The human Burkitt lymphoma-derived cell line 
Dandi, the EBV-transformed  cell line RPMI-8866, the erythromye- 
loid leukemia cell line K562,  the murine mastocytoma (Fc~R § 
cell line P815X2, and the murine antibody-secreting hybridomas 
were maintained in culture in RPMI-1640 medium (Flow Labora- 
tories, Inc., McLean, VA) supplemented with 10%  FBS (Flow 
Laboratories, Inc.). All cell lines were free of  mycoplasma  contami- 
nation on repeated testing. 
Monodonal Anabody.  Antibodies  used were OKT3 (IgG2a, anti- 
CD3), B36.1 (IgG2b, anti-CDS), 3G8 (IgG1, anti-CD16), B73.1 
(IgG1, anti-CD16), B159.5 (IgG1, anti-CD56), B52.1 (IgM, anti- 
CD14), 1366.6 (IgG1, anti-CIM), Bl16.1 (IgG2a, anti-CD8), OKT8 
(IgG2a, anti-CD8),  TCR-~I  (anti-TCP, 8 chain), TIA-2 (anti- 
CD3~, B133.1 and B133.5 (both IgG1, anti-IFN-3,), Mc.a-NAP-1 
(anti-IL-8), and Pc.a-NAP-1 (goat anti-human IL-8 antibody). An- 
tibody 3G8-producing cells were kindly provided by Dr. J. Unke- 
less (Mount Sinai School of Medicine, New York, NY); OKT3, 
OKT4, and OKT8 cells were obtained from the American Type 
Culture Collection (Rockville, MD); antibody TCtL-/~I  was kindly 
provided by Dr. M. Brenner (Harvard University, Boston, MA), 
antibody TIA-2 was provided by Dr. P. Anderson (Dana Farber 
Cancer Institute, Boston, MA), and the anti-II.-8 antibodies were 
a generous gift from Dr. M. Ceska (Sandoz Inc., Vienna, Austria); 
all other antibodies were produced and characterized in our labo- 
ratory. 
Cytokines and Cytobine  Assays.  Chinese hamster ovary cell- 
derived recombinant NK cell stimulatory factor/IL-12  (rNKSF/IL- 
12) 1 was  kindly provided by Dr.  S.  Wolf (Genetics Institute, 
Boston,  MA),  and rIL-2 (107 U/mg)  was  provided by Dr.  T. 
Taguchi (Osaka University and Takeda Chemical Industry, Inc., 
Osaka, Japan). IFN~ was measured  by ILIA  as described (40) using 
mAbs B133.1 and B133.5. ID8 was measured  by ELISA  using mAb 
Mc.a-NAP-1 and the alkaline phosphatase-conjugated goat poly- 
clonal antibody ~.a-NAP-1. 
PBL Cultures.  PBMC were obtained from peripheral blood by 
Ficoll-Hypaque density gradient centrifugation followed by a 1-h 
incubation in plastic flasks to partially deplete adherent monocytes. 
Cultured  NK cells were prepared as described (41) with some 
modifications. Briefly,  PBL were cultured in 24-well plates (Nun- 
clon, ILoskilde,  Denmark) at 2.5  x  10  s cells/ml in RPMI-1640 
medium with 10% fetal bovine serum (FBS) at 37~  in a 9.5% 
CO2 atmosphere together with the irradiated (50-Gy) RPMI-8866 
B cell line (5  x  10' cells/ml). On day 6 of culture, half of the 
medium was replaced  with fresh RPMI-1640/10% FBS and all cul- 
tures were collected  on days 8-10. NK cells (>98%  CD16+/ 
CD56 +/CD3-) were purified from 8-10-d cultures by depletion 
of T cells and monocytes  by antiglobulin rosetting with the mAbs 
OKT3, B36.1, and B52.1. Non-MHC-restricted cytotoxic CD8 § 
T cells were obtained from rlL-2 (200 U/ml)-cultured (5 d) PBL 
1 Abbreviations used in this  paper: BLT,  N-carbobenzoxy-t-lysine-thiobenzyl 
ester; FBS, fetal bovine serum; GotMIg,  goat anti-mouse  Ig; IP, inositol 
phosphate; rNKSF/IL-12,  recombinant natural killer cell stimulatory 
factor/IL-12; [3H]TdR, thymidine  [methyl-3H]. 
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ting using mAbs 3G8, B73.1, B159.5,  and B52.1 at the start and 
end of cultures. At the end of culture, the NK-depleted PBL were 
subjected to two color immunofluorescence analyses and depleted 
of CD4 + cells or CD4 + and C1.7 + cells by antiglobulin rosetting 
with mAb B66.6 or with mAbs B66.6 and C1.7, respectively. 
Two-color lmmunofluorescence Assa2/s.  The surface phenotype of 
the indicated lymphocyte populations was determined by two-color 
immunofluorescence with mAbs using an EPICS Elite cytofluoro- 
graph  (Coulter Corp.,  Hiahah,  FL). mAbs were either biotin- 
yhted (biotin-N-~uccinimide ester; Calbiochem-Novabiochem 
Corp., La Jolla, CA) or directly conjugated to FITC (International 
Biological Supplies, Melbourne, FL) according to the manufacturer's 
instructions.  Biotinyhted reagents were detected with phycoerythrin 
Streptavidin (PE-Avidin;  Coulter Corp.). 
Generation of F(a~t)2 Fragments.  mAbs C1.7 and 3G8 (1 mg/ml) 
purified by affinity chromatography on a protein G column (Phar- 
macia Fine Chemicals, Upsala, Sweden) were digested with Pepsin 
(0.05%; Sigma Chemical Co., St. Louis,  MO) for 18 h at 37~ 
in 0.1 M sodium acetate, pH 4.1. Pepsin digests were dialyzed against 
PBS and subjected to protein G column chromatography to remove 
undigested  IgG.  CommerdaUy  obtained  goat  anti-mouse  Ig 
(G~MIg) F(ab')z fragments  (Cappel Laboratories, Cochranville" 
PA) were also passed through a protein G column to remove pos- 
sible contaminating IgG. All column effluents were confirmed to 
consist of pure F(ab')2 fragments by SDS-PAGE followed by silver 
staining. 
SDS-PAGE and Western Blotting.  Purified, cultured NK cells 
were lysed with 1% NP-40, 5 mM PMSF, and 10 #g/ml leupeptin 
in PBS. The lysate equivalent of 2  x  105 cells was loaded onto 
5-20% continuous gradient polyacrylamide slab gels (1.0-mm thick- 
ness) and SDS-PAGE was performed as described (42) under non- 
reducing and reducing (2% fl-mercaptoethanol) conditions. After 
electrophoresis, resolved proteins were transferred to nitrocellulose 
using a semi-dry transblotter (Bio-Rad Laboratories,  Richmond, 
CA). The blots were cut into strips and probed with the indicated 
antibodies  that  were  detected  by  mI-labeled,  aifinity-purified 
G~xMIg. The strips were reassembed  and subjected to autoradi- 
ography. 
Cell-mediated Cytotoxicity Assays.  Chromium release assays were 
performed in U-bottomed microtiter plates (Costar Corp., Cam- 
bridge,  MA)  using  the  indicated SlCr-labeled  target  cells  (104 
cells/well) with a 3-h incubation.  All assays were performed in tripli- 
cate using four different effector cell concentrations. Results were 
quantitated by calculating the percentage of specific S~Cr release 
and in some assays the number of lyric units per 107 cells at 45% 
specific lysis were calculated using the linear regression to a modified 
Van  Krogh's equation  (43).  In  antibody-redirected lysis  assays, 
Fcq,  R + P815X2 cells were labeled with SlCr and used as targets 
in the presence of medium alone or medium with 0.1 #g/ml of 
the indicated antibodies.  In the hybridoma-redirected tysis assays, 
the PX63.AgS.653 myeloma cell line or the indicated hybridomas 
were  labeled  with  SlCr  and  used  as  target  cells.  Non-MHC- 
restricted cytotoxicity assays were Performed with  either SlCr- 
labeled Daudi or K562 target cells. 
NK Cell Lymphokine Production.  tktrified, cultured NK cells were 
incubated with P815X2 cells at a ratio of 10:1 in U-bottomed mi- 
crotiter plates  for 18 h in the presence or absence of mAb C1.7 
(0.1 #g/ml) and in medium alone or in medium supplemented with 
rib2 (100 U/rrd) or rNKSF/Ib12 (1 ng/ml).  After 18 h cell-free 
supernatants were collected and the concentrations of IFN-3' and 
IL,8 were determined by KIA and ELISA, respectively. 
N-Carbobenzoxy-L-Thiobenzfl  Ester-Esterase Assay.  N-Carbo- 
benzoxy-t-thiobenzyl ester (BLT) esterase activity in cell-free su- 
pematants was determined in a microtiter assay. Purified, cultured 
NK cells were incubated for 3 h with P815X2 cells at a ratio of 
10:1 in the presence of medium alone or medium with 0.1 #g/ml 
of the indicated antibodies.  NK cell effectors from the same donors 
were also assayed in parallel for antibody-redirected cytotoxicity of 
S~Cr-labeled P815X2 cells as described.  After incubation, 50/~1 of 
cell-free  supernatant  fluid was  added  to  100  #1 of 0.1  mg/ml 
dithiobis-2-nitrobenzoic acid and 0.1 mg/ml Not-carbobenzoxy-t- 
Lys-thiobenzyl ester (Sigma  Chemical Co.) in 0.1 M  Tris and 1 
mM MgC12, pH 7.5. BLT-esterase activity was determined by in- 
creased absorbance at 405 nm. Total BLT-esterase activity was de- 
termined from lysed (freeze/thaw three times), untreated NK cells. 
The percentage of specific BLT-esterase release was calculated as 
experimental BLT-esterase activity -  spontaneous (untreated) BLT- 
esterase activity/total BLT-esterase activity  x  100. 
Lymphocyte Proliferation Assays.  Fresh PBL or purified, cultured 
(7 d) NK cells were cultured in flat-bottomed Linbro/Titertrek 
plates  (Flow Laboratories,  Inc.)  at  105 cells/well for 6  or 3  d, 
respectively.  PBL were cultured in the presence of rNKSF/IL-12 
(0.1 ng/ml) alone or with 10, 100, or 1,000 U/m1 of rIL-2. Cells 
were either untreated or treated with the indicated soluble anti- 
bodies (1 #g/ml).  NK cells were cultured in medium alone or 
medium supplemented with 10,  100, or 1,000 U/m1 of rib2 in 
wells that were treated with 0.1  M bicarbonate buffer, pH 9.5, 
alone or bicarbonate buffer with 5 #g/m1 of the indicated anti- 
bodies. Before cells were added, the bicarbonate buffer was removed 
and the wells were washed twice with PBS to remove unadsorbed 
antibodies.  Thymidine [methyl-3H] ([3H]TdR; New England Nu- 
clear, Boston, MA) was added (1 #Ci/well) during the last  6 h 
of culture. Cells from triplicate cultures were harvested on glass 
fiber filters and [3H]TdK incorporation was determined by liquid 
scintillography. 
Phosphoinositide Turnover.  Determination ofintracellular accumu- 
lation of inositol phosphates (IP) was performed as described (44). 
Briefly,  purified NK cells  (5-10  x  10~/ml)  were incubated in 
inositol-free RPMI-1640 medium (Flow Laboratories,  Inc.) with 
5% FBS for 18 h at 37~  in the presence of myo-[~H]inositol  (10 
#Ci/ml; Amersham Corp., Arlington Heights, IL). After incuba- 
tion, cells were resuspended  in HBSS (1 mM CaC12, 5.6 mM glu- 
cose, 20 nM Hepes, and 10 mM LiC1, pH 7.4) (GIBCO BRL, 
Gaithersburg,  MD). C1.7 F(ab')2 fragments (1 #g/ml) and GcxMIg 
F(ab')2 (20 #g/ml) fragments were added at the indicated times 
to duplicate samples of 10  x  105 cells. The different IPs (IP1- 
IP4) were measured as cell-incorporated counts per minute after 
anion exchange chromatography of each sample on a 1-ml Agl-X8 
column (Bio-Rad Laboratories). Columns were washed with a four- 
step discontinuous gradient of 0.1 M formic acid containing 0.2, 
0.5, 0.8, and 1.0 M ammonium formate to elute IPl, IP2, IP3, and 
IP4, respectively.  Radioactivity of each fraction was measured by 
liquid scintillation counting in a fl counter. 
[Ca~+]~ Measurement.  [Ca2+]i  increases in NK cells were deter- 
mined as previously described (44). Briefly, NK cells were labeled 
with the fluorescent Ca  2+ indicator fura-2/AM (2 #M) (Calbio- 
chem-Novabiochem Corp.). After fura-2 loading, cells were washed 
and resuspended in HBSS and fluorescence measurements were per- 
formed in a spectrofluorometer (Perkin Elmer Corp., Norwalk, CT) 
equipped with a thermostatic cuvette holder maintained at 37~ 
with continuous stirring. Each sample contained 5  x  106 cells in 
1.7 ml of HBSS. The C1.7 F(ab')2 reagent (0.5 #g/ml final) and 
the GaMIg F(ab')2 reagent (10 #g/ml final) were added at the in- 
dicated times and changes in fluorescence were recorded as a func- 
tion of time. [Ca  2§ ]i was calculated  as previously described (44). 
1399  Valiante  and Trinchieri Results 
mAb CL 7 Reactivity with Leukocyte Subsets.  Single-color 
indirect  immunofluorescence analyses  (flow cytometry)  of 
human peripheral blood leukocytes (not shown) indicated that 
24.4  _+  2.9%  (mean  _+  SE [n  =  12])oflymphocytes were 
reactive with mAb C1.7. Monocytes stained with much lower 
fluorescence intensity  than  lymphocytes with  mAb  C1.7, 
whereas granulocytes were negative for mAb C1.7 reactivity. 
Two-color immunofluorescence analyses were performed on 
PBL preparations from 10 donors. In all experiments mAb 
C1.7  reacted  with  virtually  all  CD16 +  (Fig.  1  B)  and 
CD56 +  (not  shown)  NK  cells  and  with  51.6  _+  5.2% 
(range: 29.9-73.2%;  n  =  10) of CD3 +/CD8 + T  cells (Fig. 
1,  C  and E).  mAb C1.7  reactivity was  never observed on 
CD4 + T  cells (Fig.  1 D).  To analyze mAb C1.7 reactivity 
with  fresh peripheral blood 3'/6 +  T  cells,  which in most 
donors comprise a very low percentage of lymphocytes, PBL 
from  five donors  were  depleted of CD16 +,  CD56 +,  and 
CD4 + lymphocytes by antiglobulin rosetting and analyzed 
by two-color immunofluorescence. In these preparations TCR- 
3,/6 + cells  represented 21.2  _+  9.1%  (n  =  5)  of the total 
lymphocytes, and 62  _+  6%  (range:  45.1-81.7%)  of these 
T  cells were mAb C1.7 +  (Fig.  1, E  and F).  The intensity 
of mAb C1.7 staining and its reactivity with different lym- 
phocyte subsets were unaffected by activation or culture con- 
ditions. Activated NK cells from 8-d culture with certain EBV- 
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Figure  1.  Two-color immunofluorescence (flow cytometry)  analyses. 
PBL from a representative donor were stained with no antibody (A) or 
with biotinylated mAb C1.7 (detected with PE-avidin) and simultaneously 
with FITC-conjugated anti-CD16 (3G8) (B); anti-CD3 (OKT3) (C); anti- 
CD4 (]366.6) (D); or anti-CD8 (Bl16.1) (E) mAbs. The lymphocyte popu- 
lations from a different donor shown in F and C were depleted of CD16 +, 
CD56 +  , CD4 + cells  before analysis and stained with no antibody (F) or 
with mAb CI.7 and anti-TCR.-~ (TCR-($1) (C). 
Figure 2.  WesternblotsofNK 
cell lysates resolved under nonre- 
ducing (lanes I and 2) or reducing 
(lanes 3  and 4) conditions were 
probed with the following mAbs: 
C1.7 (lanes I  and 3) and TIA-2 
(anti-CD3~)  (lanes 2 and 4). 
transformed B cell lines, activated "y//~+ T  cells from similar 
cultures,  or  IL-2-cultured  PBL  all  remained virtually  un- 
changed in the level and distribution of mAb C1.7 staining 
(not  shown). 
Detection of  p38 in NK Cell Lysates by Western  Blotting.  1% 
NP-40 lysates from purified, cultured NK cells were resolved 
by SDS-PAGE,  transferred to nitrocellulose, and screened with 
various mAbs spedfic for NK cell proteins. Fig. 2 illustrates 
a representative blot from one donor.  As shown in Fig.  2, 
mAb C1.7 (lanes 1 and 3) detected a single immunoreactive 
species of 38 kD (p38) under both nonreducing (lane I) and 
reducing  (lane  3)  conditions.  As  shown,  the  anti-CD3~" 
(TIA-2) control (lanes 2 and 4) detected a 34-kD protein under 
nonreducing conditions (lane 2) which reduced to a single 
17-kD  immunoreactive species (lane 4). 
Effect of mAb  (7,I.7 on NK  Cell Cytotoxic Activity.  As 
depicted in Fig. 3, mAb C1.7 was able to activate NK cell 
cytotoxicity in different assay systems. Soluble mAb C1.7 was 
capable of substantially increasing both cultured (Fig. 3 A) 
and fresh (Fig. 3 B) NK cell-mediated antibody-redirected 
lysis against  the F~R + P815X2  target cells.  In all donors 
the levels  of specific SlCr release observed with mAb C1.7 
were comparable to those observed with anti-CD16  (3G8) 
treatment and,  as shown, markedly greater than those ob- 
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Figure 3.  mAb C1.7-induced, NK cell-mediated cytotoxicity. Purified, 
cultured NK cells (A) or PBL (B) were used as effectors in standard 3-h 
sICr release assays against slCr-labeled Fc'yR.  + P815X2 target cells at the 
indicated ratios. Assays  were performed in the presence of medium alone 
(O)  or  medium with  0.1  /~g/ml  of mAb B159.5 (anti-CD56)  (O), 
mAb 3G8 (anti-CD16)  (~7), or mAb C1.7 (V). Purified, cultured NK 
cells (C) were used as effectors against the slCr-labeled myeloma fusion 
partner, PX63.AgS.653  (O), or the hybridomas 3G8 (~7), B159.5 (@), 
or C1.7 (A). 
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Figure  4.  mAbC1.7-induced 
cytotoxicity and BLT-esterase re- 
lease. Purified,  cultured NK ceUs 
were  incubated  for  3  h  with 
Fc~IL + P815X2 target cells at a 
ratio of 10:1 in parallel assays for 
SlCr release (open bars) and BLT- 
esterase release (striped bars) in the 
presence  of  medium  alone  or 
medium supplemented with 0.1 
/~g/ml  of  mAb  B159.5,  mAb 
C1.7,  or mAb 3G8.  Results are 
presented as the mean percentage 
3G8  of specific release  _+ SE (n  =  4). 
served with anti-CD56 (B159.5) treatment or medium alone. 
Fig. 3 C illustrates that the C1.7 hybridoma was sensitive 
to NK cell cytotoxicity,  although in most experiments to 
a lesser extent than the anti-CD16 hybridoma (3G8). In these 
experiments, neither the anti-CD56 hybridoma (B159.5) nor 
the PX63.Ag8.653 myeloma  fusion partner were significantly 
lysed by the NK cells. The decreased efficiency of the C1.7 
hybridoma in inducing cytotoxicity  compared with the 3G8 
hybridoma could be due to the fact that the surface Ig ex- 
pression of the C1.7 hybridoma was much lower than that 
observed for the 3G8 hybridoma (not shown). 
Effect of mAb C1.7 Stimulation on BLT-Esterase Release  from 
NK Cells.  The ability of mAb C1.7 to induce the release 
of the granule enzyme BLT-esterase from cultured NK ceUs 
was determined  using a variety of stimulation protocols, mAb 
C1.7 was: (a) immobilized on a plastic support, (b) bound 
to Sepharose 4B, (c) absorbed to plastic-bound  GolMIg, or 
(d) presented to NK cells by the Fc~R + target ceU P815X2. 
Under no conditions were detectable levels of BLT-esterase 
release observed above controls after mAb C1.7 stimulation. 
By contrast, anti-CD16  stimulation resulted in substantial 
increases in  BLT-esterase levels with  all  four stimulation 
methods. Fig. 4 summarizes the results of four experiments 
in which cuhured NK cells were incubated with P815X2 ceUs 
(E/T 10:1) in the presence of medium alone or the indicated 
Table  1.  mAb C1.7-induced  Lymphokine  Production 
antibodies and assayed  in paraUd for antibody-redirected lysis 
(open Mrs) and BLT-esterase release (striped bars). Both mAb 
C1.7 and mAb 3G8 induced cytotoxic activity in the NK 
cells when compared with anti-CD56 (B159.5) and medium 
controls. However, only mAb 3G8 was capable of stimulating 
BLT-esterase  release  with no increase observed in C1.7-treated 
cultures. 
Stimulation of NK  Cell Lymphokine Production by mAb 
C1.7.  Using the same stimulation protocols used to induce 
BLT-esterase  release, the effect ofmAb C1.7 on NK cell lym- 
phokine production was examined.  Specifically, the ability 
of mAb C1.7 to induce the production of IFN-% IL-8, and 
TNF-o~ was determined by RIA and ELISA assays of 18-h- 
stimulated cell-flee supernatant fluids. The C1.7 antibody was 
capable of inducing significant increases in IFN-3, and IL-8 
production from cultured NK cells only when soluble mAb 
C1.7 (0.1/~g/ml) was presented to the NK cells by FcyR  + 
P815X2 cells. As shown in Table 1, increases  in IFN-~/produc- 
tion were observed in the presence of rlL-2 (100 U/m1) or 
rNKSF/IL-12  (1 ng/ml), whereas increases in IL-8 produc- 
tion occurred with mAb C1.7 alone or in the presence of 
rlL-2 or NKSF/IL-12. Under all stimulation conditions mAb 
C1.7 treatment had no effect on TNF-c~ production (not 
shown). Unlike mAb C1.7, anti-CD16  (3G8) treatment in- 
duced comparable lymphokine (IFN-3~ and IL-8) production 
under all four stimulation protocols and anti-CD56  (B159.5) 
treatment had no effect on IFN-~/and IL-8 production under 
any of the conditions tested (not shown). 
Effect of  mAb CI.7 Treatment  on Lymphocyte  Proliferation.  We 
analyzed the ability of both soluble and plastic-bound mAb 
C1.7 to affect [3H]TdR uptake of fresh PBL (Fig. 5 A) or 
purified, cultured (7 d) NK ceils (Fig. 5 B) alone or in the 
presence of increasing doses of rNKSF/IL-12 or rlL-2.  Fig. 
7 A demonstrates that soluble C1.7 induced a two- to four- 
fold enhancement of PBL  [3H]TdR incorporation in PBL 
cultured for 6 d in the presence of 0.1 ng/ml of rNKSF/IL- 
12 and increasing doses (10-1,000 U/ml) of rIL-2. This en- 
hancement was greater than that observed with soluble anti- 
CD3 (OKT3) treatment, but OKT3 treatment resulted in 
Treatment*  mAb C1.7  IFN-% mean U/ml  +  SE (n  =  10)  IL-8, mean pg/ml  _+  SE (n  =  6) 
Medium  -  5.2  +_  2.1  150.5  _+  50.8 
Medium  +  5.5  _+  1.1  236.4  _+ 81.3' 
rlL-2  -  61.3  _+ 8.2  251.2  +  75.2 
rlL-2  +  208.7  _+ 25.5s  550.9  _+  135.0s 
rNKSF/IL-12  -  60.6  _+  12.2  243.4  +  100.5 
rNKSF/IL-12  +  247.8  + 30.9  s  496.9  _+  161.7~ 
* Purified, cultured NK cells were incubated for 18 h with P815X2 cells (E/T, 10:1) in the presence or absence of mAb C1.7 (0.1/~g/ml). Stimulation 
was performed in medium alone or medium supplemented with rlL-2 (100 U/ml) or rNKSF/IL-12 (1 ng/ml). IFN-3,  and IL-8 concentrations were 
determined in the cell-flee supernatant fluids by ILIA or ELISA, respectively, as described.  Significance was determined by Student's t test for dependent 
samples. 
t p  <0.05. 
s p  <0.005. 
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Figure 5.  Effect  ofmAb C1.7 stimulation on lymphocyte proliferation. 
Fresh PBL (/1) or purified, cultured (7 d) NK cells (B) were cultured for 
6 or 3 d, respectively, as described. PBL (A) were cultured in the presence 
of 0.1 ng/ml of rNKSF/Ib12 and the indicated doses of rib2 in medium 
alone (O) or medium with 1 #g/ml of soluble mAb C1.7 (@) or anti- 
CD3 antibody (OKT3) (V). NK cells (B) were cuhured with the indi- 
cated doses of rIL-2 in the presence of no antibody (O) or the following 
antibodies (5/~g/ml) hound to plastic: mAb C1.7 (O), mAb 3G8 (V), 
or mAb B159.5 (V). In all experiments, NK cells incorporated far lower 
amounts of [3H]TdR than PBL. Results are presented as mean +  SE (n 
=  4). 
enhanced [3H]TdR uptake in the absence of either cytokine. 
Treatment of PBL with plastic-bound mAb C1.7 consistently 
resulted in moderately decreased [3H]TdR uptake by the cells 
(not shown). 
When purified, cultured (7 d) NK cells were treated in 
a similar fashion for 3 d, the effect of mAb C1.7 (soluble 
or plastic bound) was antagonistic to the effects of increasing 
doses of rIL-2 (Fig. 5 B) or rNKSF/IL-12 (not shown). In 
all experiments, anti-CD56 (B159.5) treatment had no effect 
on proliferation when compared with medium controls, and 
anti-CD16 (3G8) treatment, similar to what was observed 
in cultures treated with mAb C1.7,  was antiproliferative 
(Fig.  5 B). 
Signal Transduction through p38 on NK Cells.  We measured 
the ability of mAb C1.7 stimulation to initiate polyphospho- 
inositol turnover and increases in  [Ca2+]i in purified, cul- 
tured NK cells. Fig. 6 A  shows that within 15- 30 s after 
crosslinking  with  GotMIg  F(ab')2 (20  #g/ml)  the  C1.7 
F(ab')2  (1.0  #g/ml)  induced  substantial  increases  in  the 
second messenger, inositol triphosphate (IP3), followed by 
induction  of  inositol  bisphosphate  (IP2) and  inositol 
tetrakiphosphate (IP4). Similar to  the induction of poly- 
phosphoinositol turnover,  the  F(ab')2 of mAb  C1.7  (0.5 
#g/ml) induced increases in [Ca  2+ ]i after crosslinking with 
the GotMIg F(ab')2 (10 #g/ml) reagent (Fig.  6 B).  In all 
donors anti-CD16 (3G8)  stimulation resulted in low level 
generation of IPs and [Ca2+]i increases when the antibody 
was used alone and these levels were greatly increased upon 
crosslinking, consistent with our previously published results 
(44). Treatment of NK cells with the anti-CD56 antibody, 
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Figure 6.  IP formation (tl) and [Ca2+]i  increase (B) in NK cells stimu- 
lated with mAb C1.7 F(ab')~. (A) Purified NK cells were loaded with 
myo-[3H]inositiol  as described in Materials and Methods. IP1 (@), It)2 (xT), 
IP3 (V), and II)4 ([3) were extracted from the cells (10  x  106/duplicate 
samples) at the indicated times after addition of mAb C1.7 F(ab')2 (1 
#g/ml) with or without F(ab')2 GoLMIg (20 #g/ml). IPt, IP2, IP3, and 
1I)4 basal cpm values were 405, 119, 79, and 55, respectively. (B) Purified 
NK cells were loaded with the fluorescent Ca  2§ indicator fura2-AM and 
[Ca2+]i was determined as described, mAb C1.7 F(ab')2 (0.5 t~g/ml) and 
GotMIg F(ab')2 (10 ~g/ml) were added at the indicated times. 
B159.5, had no effect on either of these signal transduction 
events with or without the addition of GaMIg (not shown). 
Ability  of p38+CD8 +  T  Cells  to  Mediate  Non-MHC- 
restricted Cytotoxiciff.  Upon culture (3-6 d) with lymphokines 
such as IL-2 or NKSF/IL-12, cytotoxic T  cells acquire the 
ability to lyse target cells in a non-MHC-restricted manner. 
Because p38 is expressed by ~,50% of fresh CD8 + T cells, 
we examined whether p38 + and p38-  CD8 + T  cells, ob- 
tained from PBL cultured for 5 d in the presence of rlL-2, 
differed in their ability to mediate non-MHC-restricted cy- 
totoxicity. PBL were isolated from healthy donors, depleted 
of NK cells and monocytes by antiglobulin rosetting with 
mAb anti-CD16 (B73.1, 3G8), anti-CD56 (B159.5), and anti- 
CD14 (B52.1), and cultured for 5 d with 200 U/ml rlL-2. 
After culture, all of the NK-depleted (NK-) PBL were sub- 
jected to antiglobulin rosetting with anti-CD4 (B66.6) and 
the anti-CD16, anti-CD56,  and anti-CD14 reagents, with 
half of the cells also being rosetted with mAb C1.7. 
Fig. 7 A  shows the results of two-color immunofluores- 
cence analyses of the 5-d rlL-2 cultured NK-PBL obtained 
from a representative donor. Notably, there were no detect- 
able CD16 + cells (Fig. 7 A, I) in the cultured PBL and the 
percentage of C1.7+/CD8 + T cells (Fig. 7 A, 4) was con- 
sistent with that observed in fresh PBL. The small popula- 
tion ('~4%) of p38+/CD3 -  cells (Fig.  7 A, 2), present in 
this donor and some others, did not appear to affect the level 
of non-MHC-restricted cytotoxicity, because sorted (FACS  r 
CD3 + cells and total unsorted populations exhibited the 
same degree of non-MHC-restricted cytotoxic activity (not 
shown). Fig.  7 B summarizes the results from StCr release 
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Figure 7.  Spontaneous  cytotoxic  activity of p38 § and 
p38- CD8 § T cells. A two-color immunofluorescence 
analysis was performed with the indicated antibodies on 
rIL2-cultured (5 d), NK-depleted  lymphocytes  from a rep- 
resentative donor. (B) Cultured lymphocytes  were  depleted 
of CD4 + cells (0) or CD4 + and p38 + cells (~7) as de- 
scribed in Materials and Methods and used as effectors 
in 3-h chromium release assays against slCr-labeled  Daudi 
targets at the indicated ratios. Results are presented  as the 
mean percentage of specific SlCr release +_ SE (n  = 4). 
assays  using  CD8 +  T  cells  from  four  separate  donors  as 
effector cells against Daudi target cells, and demonstrates that 
the overwhelming majority of the non-MHC-restricted cyto- 
toxic activity of the rlL-2-cultured  CD8 + T  cells is con- 
tained  within  the p38 §  subset.  Experiments  using K562, 
THP-1, Jurkatt, U937, and P815X2 target cells yielded similar 
results (not shown). The different non-MHC-restricted cyto- 
toxic activity between p38 + and p38- CD8 § rlL-2-cultured 
T cells was not restricted to tumor-derived targets,  since vitally 
infected (varicella  zoster virus, HSV, and CMV) FS4 target 
cells were also lysed with much greater efficiency by p38 + 
than  by p38-  effectors (Chehimi,  J.,  N.  M.  Valiante,  and 
G.  Trinchieri,  unpublished  observations). 
Effect  of F(ab')2 Fragments of mAb  CI.7  on Non-MHC- 
restricted Cytotoxicity.  To assess the ability of F(ab')2  frag- 
ments of mAb C1.7 to alter non-MHC-restricted  cytotox- 
idty, various populations of lymphocytes were used as effectors 
against SlCr-labded Daudi and K562 target ceils in 3-h chro- 
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Figure  8.  Inhibition  of spontaneous cytotoxidty  by mAb C1.7 F(ab')2. 
PBL (A) or rlb2-cultured (5 d), NK-depleted  lymphocytes  (B and C) were 
used as effectors  in 3-11 chromium release assays  against SlCr-labded K562 
(A and B) or Daudi (C) target cells. Assays  were  performed  in the presence 
of mAb C1.7 F(ab')2 (O) or mAb 3G8 F(ab')2 (0) at the indicated con- 
centrations. Results are presented as mean lytic units/107 cells +  SE 
(.  =  3). 
mium release  assays. As shown in Fig.  8,  10 and 50/~g/ml 
of F(ab')2  fragments  of  mAb  C1.7  reduced  non-MHC- 
restricted cytotoxicity of fresh PBL against K562 (Fig.  8 A) 
target  cells  and of NK-depleted rlL-2  (5 d) cultured PBL 
against K562 (Fig.  8 B) and Daudi target cells (Fig.  8 C). 
This inhibition  appears  specific because 50 #g/ml  of anti- 
CD16 (3G8) F(ab')2 had no effect on the lytic ability of the 
lymphocytes. In five out of five donors, C1.7 F(ab')2 had no 
effect on the cytotoxic activity of purified, cultured NK cells 
against  Daudi and K562 target  cells (not  shown). 
Discussion 
Using a newly generated mAb (C1.7), we have identified 
a novel 38-kD signal-transducing surface molecule (p38) ex- 
pressed by all NK cells and subpopulations of CD8 + (od~) 
T  cells and 3,/6 + T  cells, lymphocyte subsets capable of cell- 
mediated cytotoxicity, p38 expression identifies the subset of 
cytotoxic lymphocytes (NK cells)  in fresh PBL capable of 
non-MHC-restricted cytotoxicity and a functionally similar 
subset in rlL-2-cuhured CD8 + T  cells.  The shared expres- 
sion of p38 by NK cells and non-MHC-restricted cytotoxic 
T cells suggests that p38 may be involved in a common cyto- 
toxic mechanism utilized by these distinct effector cell popu- 
lations. 
A small number of surface molecules have been previously 
described that  are able to trigger the cytotoxic mechanism 
of NK cells as measured by the ability of NK effectors to 
lyse hybridomas producing antibodies against these molecules 
or FcyR + target cells presenting a soluble IgG mAb. The 
C1.7 antibody producing hybridoma was selected from a panel 
of hybridomas obtained by fusion of spleen cells of human 
NK-immunized mice on the basis of its ability to be efficiently 
lysed by NK cells.  In addition,  the soluble IgG1 antibody 
C1.7 also induced NK cell-mediated, antibody-redirected lysis 
of FeyR § target cells, indicating that the p38 surface mol- 
ecule recognized by mAb C1.7 appears to be an activating 
structure on NK cells. The best-described molecule with these 
characteristics  on human  NK cells  is Fc3,RIIIA or CD16. 
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ligands (immune complexes)  results  in activation of cell- 
mediated cytotoxicity as well as release of BLT-esterase and 
lymphokines, p38-mediated activation of NK cell cytotox- 
icity differs from CD16 activation in that p38 stimulation 
under conditions that induced NK cell cytotoxic activity equal 
to or greater than that observed for CD16 stimulation did 
not result in the release of the granule enzyme BLT-esterase. 
Because BLT-esterase release is associated with NK cell de- 
granulation, the lack of BLT-esterase release from NK cells 
mediating mAb C1.7-redirected lysis suggests that the cyto- 
toxic mechanism induced by p38 stimulation may not in- 
volve extensive granule release. It has recently been demon- 
strated that non-MHC-restricted cytotoxicity mediated by 
resting and rlL-2-activated NK cells occurs through distinct 
mechanisms, in that rlL-2-activated, NK cell-mediated cy- 
totoxicity appears independent of BLT-esterase release (45). 
Our results demonstrating that mAb C1.7-redirected lysis 
does not involve BLT-esterase release may indicate that mAb 
C1.7-induced cytotoxicity occurs through a similar mecha- 
nism. Although mAb C1.7 stimulation did not induce BLT- 
esterase release, we have evidence that both mAb C1.7- and 
anti-CD16 (3G8)-induced redirected lysis results in apoptotic 
events  in  P815X2  target  cells  as  measured by  decreased 
propidium iodide staining and fragmentation of target cell 
DNA (Weinhouse, G., N. M. Valiante, and G. Trinchieri, 
unpublished observations). 
Investigation of the signal transduction pathways induced 
by p38 stimulation did not demonstrate any obvious differ- 
ence between p38- and CD16-mediated signal transduction 
that would account for p38's inability to initiate BLT-esterase 
release. Both p38 and CD16 stimulation resulted in the rapid 
hydrolysis  of phosphatidylinositol 4,5-bisphosphate (PlP~.) 
and increases in [Ca2+]i, as weU as activation of phospholi- 
pase D  (Valiante, N. M., M. Rengaraju, and G. Trinchieri, 
unpublished observations).  Unlike CD16-mediated signal 
transduction, which is directly activated at low levels  by soluble 
anti-CD16 antibodies and is substantially enhanced after cross- 
linking, p38-mediated signal transduction was observed only 
after crosslinking of F(ab')2 fragments of mAb C1.7 with 
F(ab')2 fragments of a GotMIg second antibody. We were 
unable to show signal-transducing activity of p38 on fresh 
and short-term cultured (rIL-2 or rNKSF/IL-12) T cells. How- 
ever, leukemic T  cell lines (TALL 103/2 [TCR-3~//~  +  ] and 
TALL  104  [TCR-a/B+])  that  express  p38  and  exhibit 
non-MHC-restricted cytotoxic activity were shown to mediate 
mAb C1.7-redirected lysis (Cesano, A., and N. M. Valiante, 
unpublished observations). 
NK cells are potent producers of lymphokines, and this 
activity can be induced by many stimuli that also activate 
their lytic mechanisms, such as perturbation of Fc3'RIII 
(CD16)  (44,  46, 47).  Stimulation with the C1.7 antibody 
resulted in production of IFN-3~ and IL-8 by NK cells which, 
similar to CD16-induced lymphokine production, was max- 
imal in the presence of other lymphokine-inducing stimuli 
such as rNKSF/IL-12 or rIL-2. Unlike anti-CD16-induced 
cytokine production,  which  is  stimulated by  antibodies 
presented on any solid support, p38-stimulated IFN-3' and 
IL-8 production only occurred when mAb C1.7 was presented 
to the NK cells by an FcqrR + cell line.  It is possible  that 
mAb C1.7-induced lymphokine production requires  acces- 
sory molecular interactions between other receptor-ligand 
pairs on the NK cells and presenting target cells which were 
not available when mAb C1.7 was presented on inert sup- 
ports such as plastic surfaces or Sepharose beads. In addition, 
the fluidity of the presenting cell membrane in comparison 
to the rigidity of a solid support might also contribute to 
more efficient stimulation. 
Treatment of fresh PBL with soluble mAb C1.7 resulted 
in enhanced thymidine uptake in the presence of rNKSF/IL- 
12 and rlL-2. However,  we did not observe any consistent 
expansion of the number of C1.7 + cells in the cultures when 
compared with untreated controls. On cultured NK cells, 
mAb C1.7 treatment was antagonistic to rNKSF/IL-12- and 
rlL-2-induced proliferation,  similar to that observed for anti- 
CD16 (mAb 3G8) treatment. The opposing effects of p38 
stimulation on these lymphocyte preparations may indicate 
that p38 modulates proliferation differently depending on the 
cell type or level of activation. 
Cultured (rlL-2;  5 d) CD16/CD56-  and CD4-depleted 
CD8 + T cells displayed a high level of non-MHC-restricted 
cytotoxic activity. Our results, demonstrating that depletion 
of the p38 + population from these cultured CD8 + T cells 
almost completely abolishes this activity,  suggest that p38 
may be a marker for non-MHC-restricted cytotoxic T cells. 
Given that p38 is present on both fresh and activated CD8 § 
T cells, it is likely that other activation events are required 
for the generation of non-MHC-restricted cytotoxic T cells. 
However, taken as a whole, our results suggest that p38 may 
not only be a marker for non-MHC-restricted cytotoxic T 
cells, but also may be required for this activity. 
The observation that F(ab')2 fragments of mAb C1.7 sub- 
stantially inhibited non-MHC-restricted cytotoxicity medi- 
ated by fresh PBL and rlL-2-activated T cells suggests that 
p38  may be  involved in  target  cell  recognition by  these 
non-MHC-restricted cytotoxic cells. F(ab')2 fragments of 
mAb C1.7 did not inhibit spontaneous cytotoxicity medi- 
ated by purified, cultured NK cells, suggesting that once ac- 
tivated, NK cells may utilize multiple or alternative mecha- 
nisms for cytotoxicity. The effects of F(ab')2 fragments of 
antibodies directed against cytotoxic lymphocyte surface mol- 
ecules can be either enhancing or inhibitory to cytotoxicity, 
depending on the type of surface molecule recognized by the 
antibody. It has been postulated that F(ab')2 fragments of 
antibodies directed against activating structures or adhesion 
molecules inhibit cytotoxicity, whereas F(ab')2 fragments of 
antibodies  directed  against  inhibitory  receptors  enhance 
cytotoxicity, perhaps by blocking the delivery of a negative 
signal (48). 
The p38 surface molecule identified by mAb C1,7 appears 
to be an activating structure on cytotoxic lymphocytes similar 
in this ability to other previously identified surface molecules, 
but distinct from these other molecules based on its unique 
leukocyte distribution and structure. The potential ligands 
for p38 have not been investigated.  However,  if p38 is in- 
volved in cell-mediated cytotoxicity, as is suggested by our 
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pressed by a number of NK-sensitive targets. Although a few 
surface molecules have recently been identified that may have 
a role in spontaneous cytotoxicity, the mechanism by which 
NK cells and other non-MHC-restricted cytotoxic cells recog- 
nize target cells still remains poorly defined, and it is likely 
that multiple mechanisms may exist. The restricted expres- 
sion of p38 to cells with non-MHC-restricted cytotoxic ac- 
tivity, its ability to activate these cells cytolytically, and the 
fact that F(ab')2 fragments of the anti-p38 antibody C1.7 in- 
hibit the spontaneous cytototxic activity of some effector popu- 
lations suggest that the p38 surface molecule may be directly 
involved in the mechanisms of non-MHC-restricted cyto- 
toxicity. 
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